WO2000003699A3 - Arzneimittel mit einem gehalt an phosphonsäurederivaten als wirkstoff und ihre verwendung - Google Patents

Arzneimittel mit einem gehalt an phosphonsäurederivaten als wirkstoff und ihre verwendung Download PDF

Info

Publication number
WO2000003699A3
WO2000003699A3 PCT/EP1999/004832 EP9904832W WO0003699A3 WO 2000003699 A3 WO2000003699 A3 WO 2000003699A3 EP 9904832 W EP9904832 W EP 9904832W WO 0003699 A3 WO0003699 A3 WO 0003699A3
Authority
WO
WIPO (PCT)
Prior art keywords
active ingredient
phosphoric acid
drugs containing
acid derivatives
containing phosphoric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/004832
Other languages
English (en)
French (fr)
Other versions
WO2000003699A2 (de
Inventor
Jomaa Hassan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU50348/99A priority Critical patent/AU5034899A/en
Publication of WO2000003699A2 publication Critical patent/WO2000003699A2/de
Publication of WO2000003699A3 publication Critical patent/WO2000003699A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)

Abstract

Die Erfindung betrifft Arzneimittel mit einem Gehalt an mindestens einem Phosphonsäurederivat der allgemeinen Formel (I), wobei B der Formel (V), der Formel (VI) oder der Formel (VII) entspricht, und deren pharmazeutisch akzeptablen Salzen, Estern und Amiden und Salze der Ester als Wirkstoff. Sie betrifft ferner die Verwendung zur Herstellung dieser Arzneimittel für die prophylaktische und therapeutische Behandlung von Infektionen durch Viren, Pilze, Bakterien oder Parasiten.
PCT/EP1999/004832 1998-07-15 1999-07-09 Arzneimittel mit einem gehalt an phosphonsäurederivaten als wirkstoff und ihre verwendung Ceased WO2000003699A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU50348/99A AU5034899A (en) 1998-07-15 1999-07-09 Drugs containing phosphoric acid derivatives as active ingredient and their use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19831638 1998-07-15
DE19831638.0 1998-07-15

Publications (2)

Publication Number Publication Date
WO2000003699A2 WO2000003699A2 (de) 2000-01-27
WO2000003699A3 true WO2000003699A3 (de) 2000-08-10

Family

ID=7874068

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/004832 Ceased WO2000003699A2 (de) 1998-07-15 1999-07-09 Arzneimittel mit einem gehalt an phosphonsäurederivaten als wirkstoff und ihre verwendung

Country Status (2)

Country Link
AU (1) AU5034899A (de)
WO (1) WO2000003699A2 (de)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2733658A1 (de) * 1976-07-27 1978-02-09 Fujisawa Pharmaceutical Co Hydroxylaminohydrocarbylphosphonsaeurederivate, verfahren zur herstellung derselben und diese enthaltende pharmazeutische mittel
US4206156A (en) * 1976-07-27 1980-06-03 Fujisawa Pharmaceutical Company, Limited Hydroxyaminohydrocarbonphosphonic acids
DE2941384A1 (de) * 1979-10-12 1981-04-23 Bayer Ag, 5090 Leverkusen Phosphono-hydroxy-essigsaeure, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
EP0256785A2 (de) * 1986-08-11 1988-02-24 Fujisawa Pharmaceutical Co., Ltd. Herbizides Mittel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2733658A1 (de) * 1976-07-27 1978-02-09 Fujisawa Pharmaceutical Co Hydroxylaminohydrocarbylphosphonsaeurederivate, verfahren zur herstellung derselben und diese enthaltende pharmazeutische mittel
US4206156A (en) * 1976-07-27 1980-06-03 Fujisawa Pharmaceutical Company, Limited Hydroxyaminohydrocarbonphosphonic acids
DE2941384A1 (de) * 1979-10-12 1981-04-23 Bayer Ag, 5090 Leverkusen Phosphono-hydroxy-essigsaeure, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
EP0256785A2 (de) * 1986-08-11 1988-02-24 Fujisawa Pharmaceutical Co., Ltd. Herbizides Mittel

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
H.C.NEU ET AL.: "In Vitro and In Vivo Antibacterial Activity of FR-31564, a Phosphonic Acid Antimicrobial Agent", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 19, no. 6, 1981, pages 1013 - 1023, XP002113260 *

Also Published As

Publication number Publication date
WO2000003699A2 (de) 2000-01-27
AU5034899A (en) 2000-02-07

Similar Documents

Publication Publication Date Title
WO2004005286A3 (en) Viral inhibitors
BG103945A (bg) Производни на 4"-заместен-9-деоксо-9а-аза-9а- хомоеритромицин а
CA2421120A1 (en) Quinolinone derivatives as tyrosine kinase inhibitors
CA2183972A1 (en) Oxazolidinone derivatives and pharmaceutical compositions containing them
CA2396561A1 (en) Substituted oxazolidinones and their use in the field of blood coagulation
CA2320233A1 (en) Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof
AU1025795A (en) Prolineamide derivatives
HK129093A (en) N-tert-butyl-decahydro-2(3-amino-2-hydroxy-4-phenyl-butyl)isoquinoline-3-carboxamide & asparaginyl derivatives thereof
WO2001027111A3 (de) Bicyclische imidazo-3-yl-aminderivate
CA2336412A1 (en) Medicament for treatment of diabetes
HK1042303A1 (zh) 新的化合物
RU2002100058A (ru) Кристаллические производные 1-метилкарбапенема
WO1992019211A3 (en) Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same
WO2001000617A3 (en) Novel piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same, and a process for the preparation of the same
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
WO2002000166A3 (en) New compounds useful as antibacterial agents
ATE310010T1 (de) 6-0-substitutierte eryththromycin-verbindungen und verfahrenen zu ihrer herstellung
PT1218401E (pt) 4-benzilaminoquinolinas conjugadas com acido biliar e seus heterociclicos metodos de sua producao medicamentos contendo estes compostos e sua aplicacao
HK1042493A1 (zh) 新的化合物
WO2001005386A3 (en) Pharmaceutical composition useful for the treatment of tinnitus and hearing loss
EP1325748A4 (de) Prophylaktische oder therapeutische arzneimittel gegen krebs enthaltend cyanidinverbindungen als wirkstoff
CA2382654A1 (en) Novel a-500359 derivatives
WO2000003699A3 (de) Arzneimittel mit einem gehalt an phosphonsäurederivaten als wirkstoff und ihre verwendung
WO2002006299A3 (en) Therapeutic uses for aminosterol compounds
CA2133186A1 (en) 3- or 4-glycosyloxybenzopyran derivative and antiallergic agent containing the derivative as active ingredient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase